Neuphoria Therapeutics

NASDAQ: NEUP ↗$3.64 USD~$5M (post-Merck-discontinuation, July 2026) MCAP

#Alzheimer's Disease #CNS / Neuropsychiatric Disorders #Neurodegenerative Disease #Adjunctive Therapy

Neuphoria Therapeutics is a clinical-stage biopharmaceutical company developing CNS-focused therapeutics for neuropsychiatric and neurodegenerative conditions. The company's lead partnered program MK-1167, an adjunctive Alzheimer's disease therapy being co-developed with Merck under a 2022 partnership, was discontinued in mid-2026 after a planned interim Phase 2 efficacy review. This was the second Merck-Neuphoria compound to be discontinued (MK-4334 was previously shelved in 2022), effectively ending the partnership.

Company Info

Sector:Biopharmaceuticals / CNS & Neurodegenerative Disease

Headquarters:Burlington, Massachusetts, USA

Founded:2022

Website:www.neuphoria.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Q2 2026 financial results and pipeline strategic review following Merck-partnership discontinuation

Clinical Development Pipeline

MK-1167 (Merck partnership)

Target: Adjunctive CNS mechanism (undisclosed; partnered with Merck)

Adjunctive Alzheimer's disease (mild-to-moderate, on top of standard-of-care) — Phase 2 DISCONTINUED June 2026 after interim efficacy review

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Spyros Papapetropoulos

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Burlington, MA

Apply Now →